secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001213900-25-002847
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical reports 5,997,246 shares outstanding; updates on clinical and commercial progress
--------------------------------------------------------------------------------

- As of Dec 31, 2024, common shares outstanding: 5,997,246 (Jan 8, 2025: 5,977,246).
- QUELIMMUNE (SCD-PED) FDA-approved Feb 2024; first commercial shipment July 2024; 4 hospital customers as of Q1 2025.
- NEUTRALIZE-AKI adult pivotal trial 37% enrolled (74 of 200 subjects); 14 of 30 sites activated; CMS covers trial costs.
- Four FDA Breakthrough Device Designations: adult AKI, cardiorenal syndrome w/ LVAD, hepatorenal syndrome, chronic dialysis.
- Zero interest-bearing debt; cash use $11.3M YTD through Q3 2024; raised ~$20M new equity through Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000121390025002847/0001213900-25-002847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000121390025002847/ea0227427-8k_seastar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-002847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer